Liaoning Boao Biopharmaceutical Co., Ltd. was founded in 2010, located in Benxi Economic and Technological Development Zone, National Liaoning (Benxi) Biomedical Industry Base, is a modernized biopharmaceutical enterprise integrating R&D and production of insulin series products. Covering an area of 35,000 square meters and a building area of 20,000 square meters, it has fixed assets of nearly 200 million yuan.
Liaoning Boao Bio-pharmaceutical Co., Ltd. always takes human health as its purpose, and takes serving the society and returning the society as its responsibility. We strive to take an innovative path in the field of biopharmaceuticals. Under the premise of constantly introducing high-tech talents, it has developed the world's leading recombinant protein drug recombinant human insulin, as well as its long-acting analog Glycine Insulin and fast-acting analog Menthol Insulin.
Relying on the policy advantages, regional advantages, as well as the existing talents and scientific and technological advantages, Liaoning Boao Bio-pharmaceutical Co., Ltd. has gradually developed into a modernized pharmaceutical enterprise with intensive technology, standardized management, first-class products and reliable quality in a short period of time.
The insulin series products independently researched and developed by Liaoning Boao Bio-pharmaceutical Co., Ltd. have the following characteristics compared with similar products sold in the international and domestic markets:
On behalf of all the staff of Boao, I would like to express my heartfelt thanks to all the people from all walks of life for their long-term attention and support. I would like to express my heartfelt thanks. We are willing to join hands with friends from all walks of life to create the future, warp knitting Shengye, Yiqi Boao, return the society and benefit the party.
Liaoning Boao Bio-pharmaceutical Co., Ltd. was founded in 2010 in Shenben New City, Liaoning, the "Pharmaceutical Capital of China" (a national biomedical industry base), as a modernized enterprise integrating R&D and production of insulin series products.
It is a modernized enterprise integrating R&D and production of insulin series products, and is a leading enterprise of biopharmaceuticals in Liaoning Province. It is a modern enterprise integrating R&D and production of insulin series products, and is a leading enterprise of biopharmaceuticals in Liaoning Province. It has fixed assets of nearly 200 million yuan, covers an area of 35,000 square meters and a building area of 20,000 square meters.
Liaoning Boao Bio-pharmaceutical Co., Ltd. always takes human health as the purpose, and takes serving the society and repaying the society as its responsibility. We strive to take an innovative path in the field of biopharmaceuticals. On the premise of constantly introducing high-tech talents
On the premise of constantly introducing high-tech talents, we have developed the world's leading biopharmaceutical recombinant human insulin and its long-acting analogs, insulin glargine and insulin menthol.
Relying on the policy advantages, geographical advantages, as well as the existing talents and scientific and technological advantages, Liaoning Boao Bio-pharmaceutical Co., Ltd. has gradually developed into a modernized pharmaceutical enterprise with intensive technology, standardized management, first-class products and reliable quality in a short period of time.
 | Address: No.55 Shennong Street, Benxi Economic and Technological Development Zone |  | Tel：024-47171021 |  | E-mail：lnboao@163.com |